Alvotech, AbbVie Deal Allows For Humira Biosimilar In 2023
Icelandic biopharmaceutical firm Alvotech has settled an intellectual property fight with AbbVie Inc. over Alvotech's proposed biosimilar version of AbbVie's blockbuster drug Humira, which is used to treat arthritis and other...To view the full article, register now.
Already a subscriber? Click here to view full article